Krilogy Financial’s Stemline Therapeutics, Inc. STML Stock Holding History

Krilogy Financial’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-300	Closed	-$3K	–	862
2017 Q3	$3K	Hold	300	–	–	﹤0.01%	716
2017 Q2	$3K	Hold	300	–	–	﹤0.01%	650
2017 Q1	$3K	Hold	300	–	–	﹤0.01%	636
2016 Q4	$3K	Hold	300	–	–	﹤0.01%	636
2016 Q3	$3K	Hold	300	–	–	﹤0.01%	651
2016 Q2	$2K	Hold	300	–	–	﹤0.01%	695
2016 Q1	$1K	Hold	300	–	–	﹤0.01%	668
2015 Q4	$2K	Hold	300	–	–	﹤0.01%	389
2015 Q3	$3K	Buy	+300	New	+$3.15K	﹤0.01%	530

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Krilogy Financial's STML Position: Q4 2017 in Review

Krilogy Financial sold out of Stemline Therapeutics, Inc. (STML) in Q4 2017, closing a stake of 300 shares — an estimated $3K sold.

Krilogy Financial first reported a position in STML in Q3 2015 and held it in 9 quarters. The position peaked at $3K in Q3 2017. 80 funds tracked by Wall St. Rank hold STML as of Q4 2017.

Krilogy Financial reported no remaining Stemline Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Krilogy Financial sold 300 Stemline Therapeutics, Inc. shares in Q4 2017, an estimated $3K.
Krilogy Financial first reported a position in Stemline Therapeutics, Inc. in Q3 2015 and held it in 9 quarters.
Krilogy Financial's Stemline Therapeutics, Inc. position peaked at $3K in Q3 2017.
80 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2017.

Based on Krilogy Financial's 13F filing for Q4 2017, filed 14 Feb 2018.